Comparing Dysmenorrhea in Women Using Copper T and Mirena IUD as Contraceptive Method

Document Type : Original Article

Authors

1 M.Sc. Student of Midwifery, Faculty of Medicine, Tarbait Modares University, Tehran, Iran

2 Professor of Obstetrics & Gynecology, Vali-Asr Reproductive Health Research Center, Faculty of Medicine, Tehran University of medical sciences, Tehran, Iran

3 Assistant Professor of Mother &Child Health, Mother &Child Research Center, Faculty of Medicine, Tehran University of medical sciences, Tehran, Iran

4 M.Sc. Midwife, Faculty of Medicine, Tehran University of medical sciences, Tehran, Iran

5 Associate Professor of Obstetrics & Gynecology, Vali- Asr Reproductive Health Research Center, Faculty of Medicine, Tehran University of medical sciences, Tehran, Iran

6 Associate Professor of Social Medicine, Iranian Institute for Health Sciences Research, Faculty of Medicine, Tehran University of medical sciences, Tehran, Iran

7 Medical student, Faculty of Medicine, Mashhad University of medical sciences, Mashhad, Iran

Abstract

Introduction: Dysmenorrhea is a common gynecologic disorder that at least half of women experience it during their reproductive period. Treatments, which are based on prostaglandin reduction, can be used to treat dysmenorrhea. Levonorgestrel-releasing intra uterine device (IUD) known as Mirena is one of these treatments that decrease the synthesis of endometrial prostaglandins. This study was performed in order to assess the frequency of dysmenorrhea in women using copper IUDs compared to those using Mirena IUDs.
 
Methods: This double-blind randomized clinical trial was performed on 160 women aged between 20 to 35 years who referred to Shahid Ayat Health Center (2006 and 2007) and decided to use IUDs as contraceptive method. Subjects were randomly divided into two groups of 80 cases, group A (insertion Mirena IUD) and group B (insertion copper 380-A IUD). Dysmenorrhea was assessed by designed questionnaires at first, and then 1, 3 and 6 months after insertion. Data were analyzed using Chi square, student t-test and repeated measure variance analysis by SPSS11.5.
 
Results: Dysmenorrhea significantly decreased in both groups six months after IUD insertion compared to the first month (P<0.001). However, statistically, Mirena IUD reduced dysmenorrhea faster and earlier compared to cupper IUD (P<0.003).
 
Conclusion: Levonorgestrel-releasing IUD can be used in young women to treat drug resistant dysmenorrhea, not only as a means of preventing dysmenorrhea, but also as a contraceptive method.
 
 

Keywords

References

1.  Stubblefield PG, Carr­ellis S, Kapp N. Family Planning. In: Break JS. Berek & Novak's gynecology. 15th
ed. Philadelphia:Lippincott Williams & Wilkins;2007:p. 247­311. 
2.  Cunningham FG, Leveno KJ. Wenstrom KD. Williams obstetrics. 23nd ed. New York, McGraw­Hill; 2010:  p.686 . 
3.  Wildemeersch D, Schacht  E. Endometrial suppression with a new ' frameless' levonorgestrel  releasing
intrauterine system  in perimenopausal  and postmenopausal women: a pilot study.  Maturitas  2000
Jul;36(1):63­8. 
4.  Decherney A, Nathan L.  Current  obstetric &  gynecologic: diagnosis &  treatments.  New York: Lange Medical Books; 2000:238­ 9. 
5.  El­Minawi AM, Howard FM. In: Howard FM, Perry CP, Carter JE, El­Minawi AM. Pelvic pain: diagnosis and treatment. Philadelphia: Lippincott Williams & Wilkins;2000: p. 100­7. 
6.  Jimenez MF, Arbo E, Vetori D, de Freitas FM, Cunha­Filho JS. The effect of the levonorgestrel­releasing
intrauterine system  and copper intrauterine device on subendometrial microvascularization and uterine
artery blood flow. J Fertil Steril 2008 Nov;90(5):1574­8. 
7.  Lethaby AE, Cook I,  Rees M.  Progesterone or progestoges­releasing intrauterine system  for heavy menstrual bleeding. Cochrane Database Syst Rev ntraception 2005 Oct 19;4:CD002126.
 
8.  Fedele L , Bianchi S , Zanconato G , Portuese A , Raffaellio. Use of a levonorgestrel­releasing intrauterine 
device in the treatment of rectovaginal endometriosis. Fertil Steril 2001 Mar;75(3):4858. 
9.  Thonneau PF, Almont T.  Contraceptive efficacy of intrauterine devices. Am J Obstet Gynecol 2008
Mar;198(3):248­53. 
10.  Gupta HP, Singh U, Sinha S. Levonorgestrel intra­uterine system­­a revolutionary intra­uterine device. J
Indian Med Assoc 2007 Jul;105(7):380, 382­5. 
11.  Lumsden MA, Kelly RW, Baird DT. Primary dysmenorrhea: the importance of both prostaglandins E2 and
F2 alpha. Br J Obstet Gynecol 1983 Dec;90(12):1135­40. 
12.  Strömberg P, Äkerlund M, Forsling ML,  Kindahl H.  Involvement  of prostaglandins  in vasopressin
stimulation of the human uterus. Br J Obstet Gynecol 1983 Apr;90(4):332­7. 
13.  Wildemeersch D, Schacht  E.  Treatment  of menorrhagia with a novel  ‘frameless’ intrauterine
levonorgestrel­releasing drug delivery system: a pilot study . Eur J Contracept & Reprod Health Care 2001
Jun;6(2):93­101. 
14.  Wildemeersch D, Schacht E. Contraception with a novel ‘frameless’ intrauterine levonorgestrel­ releasing 
drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2000 Dec;5(4):234­40. 
15.  Sitruk­Ware R,  Inki P. The levonorgestrel intrauterine system:  long­term  contraception and therapeutic
effect. Womens Heath (London Engl) 2005 Sep;1(2):171­82.

Files

Share

How to cite

Statistics